Willem G. van Ginkel

Neurocognitive outcome in tyrosinemia type 1 patients compared to healthy controls

Willem G. van Ginkel, Rianne Jahja, Stephan C. J. Huijbregts et al. · Orphanet Journal of Rare Diseases · 2016 · 73 citations · Full text

Medicine, Neurology, Neuroscience +17

Hepatocellular Carcinoma in Tyrosinemia Type 1 Without Clear Increase of AFP

Willem G. van Ginkel, Annette Gouw, Eric J. van der Jagt et al. · PEDIATRICS · 2015 · 29 citations

Medicine, Oncology, Pathology +17

Emotional and behavioral problems, quality of life and metabolic control in NTBC-treated Tyrosinemia type 1 patients

Kimber van Vliet, Willem G. van Ginkel, Rianne Jahja et al. · Orphanet Journal of Rare Diseases · 2019 · 27 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Daily variation of NTBC and its relation to succinylacetone in tyrosinemia type 1 patients comparing a single dose to two doses a day

Nienke S. Kienstra, Hannah E. van Reemst, Willem G. van Ginkel et al. · Journal of Inherited Metabolic Disease · 2017 · 21 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +9

The increasing importance of LNAA supplementation in phenylketonuria at higher plasma phenylalanine concentrations

Danique van Vliet, Els van der Goot, Willem G. van Ginkel et al. · Molecular Genetics and Metabolism · 2021 · 13 citations · Full text

Life Sciences, Biochemistry, Nutritional Sciences +12